Forschungsprojekte und Publikationen der German Breast Group
Die German Breast Group erforscht Brustkrebs und setzt dafür selbst entwickelte Studienkonzepte um.
Mit zusätzlichen wissenschaftlichen Forschungsprojekten wollen wir weitere Erkenntnisse über die Krankheit gewinnen.
Neuste Forschungsnachrichten
08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
27.09.2019 September 2019: Impact of post-mastectomy radiotherapy (RT) after neoadjuvant chemotherapy (NACT) on survival in breast cancer patients
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
17.09.2019 GBG Forschung beim ESMO 2019
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
12.09.2019 August 2019: Results of a pooled analysis from two randomized phase III trials [LEA GBG51 and Cancer and Leukemia Group (CALGB) 40503] evaluating the addition of bevacizumab to endocrine therapy (ET) as first-line treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC)
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
31.07.2019 July 2019: Fatal events occurring during study treatment: a pooled analysis of death cases within GBG led breast cancer trials
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer